Results 191 to 200 of about 125,339 (239)
Portal Hypertension &Cirrhosis, EarlyView.Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang +10 more
wiley +1 more source
Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. [PDF]
Diabetes Metab Res RevLee N, Kim Y.
europepmc +1 more source
From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies
Portal Hypertension &Cirrhosis, EarlyView.This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu +5 more
wiley +1 more source
Body Contouring in the Era of GLP-1 Therapy: Are We Ignoring Tissue Biology? [PDF]
Plast Surg (Oakv)Tomaselli F, Albanese R, Tambasco D.
europepmc +1 more source
AlphaFold2‐Guided Cyclic Peptide Stabilizer Design to Target Protein–Protein Interactions
Proteins: Structure, Function, and Bioinformatics, EarlyView.ABSTRACT The control and modulation of protein–protein interactions (PPIs) is of central importance for the majority of biological processes and most biomedical applications. Stabilization of PPIs, besides inhibition, is of growing pharmaceutical interest.
Niklas Halbwedl, Martin Zacharias
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 606-615, March 2025.ABSTRACT Type 2 diabetes (T2D) is a progressive metabolic disorder that could be an underlying cause of long‐term complications that increase mortality. The assessment of the probability of such events could be essential for mortality risk management. This work aimed to establish a framework for risk predictions of macrovascular complications (MVC) and
Hanna Kunina +2 more
wiley +1 more source
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. [PDF]
Int J Mol SciGandhi A +4 more
europepmc +1 more source
Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha (Withania somnifera)
Phytotherapy Research, EarlyView.Sensoril, an aqueous root and leaf extract of ashwagandha showed no evidence of mutagenicity in the in vitro Ames assay, was negative in the in vitro micronucleus, in vivo mammalian bone marrow chromosome aberration assays, and was well tolerated in the rat at up to 4000 mg/kg BW/day when administered orally for a period of 90 days. The data from these
Mukesh Summan +2 more
wiley +1 more source
GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. [PDF]
Sci ProgGupta AK +3 more
europepmc +1 more source
Phytochemicals in MASLD: A Focused Review of Gut Microbiome‐Linked Mechanisms
Phytotherapy Research, EarlyView.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as a major global health burden, yet effective pharmacological options remain limited. Recent advances highlight the gut microbiome as a key modulator of liver metabolism, inflammation, and fibrosis, making it a promising therapeutic target.
Jeong In Seo, Su Min Kim, Hye Hyun Yoo
wiley +1 more source